Phase 3 trial of transplantation of human islets in type 1 diabetes complicated by severe hypoglycemia

Diabetes Care

Volumn 39, Issue 7, 2016, Pages 1230-1240

  Hering, Bernhard J ^a   Clarke, William R ^b   Bridges, Nancy D ^c   Eggerman, Thomas L ^d   Alejandro, Rodolfo ^e   Bellin, Melena D ^a   Chaloner, Kathryn ^b   Czarniecki, Christine W ^c   Goldstein, Julia S ^c   Hunsicker, Lawrence G ^b   Kaufman, Dixon B ^f   Korsgren, Olle ^g   Larsen, Christian P ^h   Luo, Xunrong ⁱ   Markmann, James F ^j   Naji, Ali ^k   Oberholzer, Jose ^l   Posselt, Andrew M ^m   Rickels, Michael R ^k   Ricordi, Camillo ^e   Robien, Mark A ^c   Senior, Peter A ⁿ   James Shapiro, A M ⁿ   Stock, Peter G ^m   Turgeon, Nicole A ^h   more..

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^g UPPSALA UNIVERSITY   (Sweden)

^h EMORY UNIVERSITY   (United States)

ⁱ NORTHWESTERN UNIVERSITY   (United States)

^j MASSACHUSETTS GENERAL HOSPITAL   (United States)

^k UNIVERSITY OF PENNSYLVANIA   (United States)

^l UNIVERSITY OF ILLINOIS HOSPITAL AND HEALTH SCIENCES SYSTEM   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ UNIVERSITY OF ALBERTA   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; C PEPTIDE; HEMOGLOBIN A1C; RAPAMYCIN; TACROLIMUS; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ABDOMINAL PAIN; ADULT; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CYTOKINE RELEASE; CYTOPENIA; DISEASE DURATION; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DYSFUNCTION; LOW DRUG DOSE; MALE; MULTICENTER STUDY; PANCREAS ISLET TRANSPLANTATION; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; SAFETY; SERUM SICKNESS; SIDE EFFECT; URTICARIA; VOMITING; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 1; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; NORTH AMERICA; PROCEDURES; YOUNG ADULT;

ADULT; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; IMMUNOSUPPRESSION; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; MIDDLE AGED; NORTH AMERICA; YOUNG ADULT;

EID: 84975832571     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-1988     Document Type: Article

References (40)

1. Cryer PE. Glycemic goals in diabetes: tradeoff between glycemic control and iatrogenic hy-poglycemia. Diabetes 2014;63:2188-2195
2. Seaquist ER, Anderson J, Childs B, et al. Hy-poglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 2013;36:1384-1395
3. Geddes J, Schopman JE, Zammitt NN, Frier BM. Prevalence of impaired awareness of hypo-glycaemia in adults with type 1 diabetes. Diabet Med 2008;25:501-504
4. Hopkins D, Lawrence I, Mansell P, et al. Improved biomedical and psychological outcomes 1 year after structured education in flexible insulin therapy for people with type 1 diabetes: the U.K. DAFNE experience.Diabetes Care 2012; 35:1638-1642
5. Weinstock RS, Xing D, Maahs DM, et al.; T1D Exchange Clinic Network. Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry. J Clin Endocrinol Metab 2013;98:3411-3419
6. Frier BM. Hypoglycaemia in diabetes melli-tus: epidemiology and clinical implications. Nat Rev Endocrinol 2014;10:711-722
7. Choudhary P, Rickels MR, Senior PA, et al. Evidence-informed clinical practice recommendations for treatment of type 1 diabetes complicated by problematic hypoglycemia. Diabetes Care 2015;38:1016-1029
8. Yeoh E, Choudhary P, Nwokolo M, Ayis S, Amiel SA. Interventions that restore awareness of hypoglycemia in adults with type 1 diabetes: a systematic review and meta-analysis. Diabetes Care 2015;38:1592-1609
9. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care 2012;35(Suppl. 1):S11-S63
10. Byrne ML, Hopkins D, Littlejohn W, et al. Outcomes for adults with type 1 diabetes referred with severe hypoglycaemia and/or referred for islet transplantation to a specialist hypoglycaemia service. Horm Metab Res 2015; 47:9-15
11. Miller KM, Foster NC, Beck RW, et al.; T1D Exchange ClinicNetwork. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care 2015;38:971-978
12. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free im-munosuppressive regimen. N Engl J Med 2000; 343:230-238
13. Hering BJ, Kandaswamy R, Ansite JD, et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA 2005;293:830-835
14. Shapiro AM, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006;355: 1318-1330
15. Food and Drug Administration Center for Biologics Evaluation and Research. Biological Response Modifiers Advisory Committee (BRMAC) meeting 36 [article online], 2003. Available from http://www.fda.gov/ohrms/dockets/ac/03/transcripts/3986T1.htm. Accessed 20 October 2015
16. U.S. Food and Drug Administration. Guidance for Industry: Considerations for Allogeneic Pancreatic Islet Cell Products [article online], 2009. Available from http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/ucm182440.htm. Accessed 20 October 2015
17. American Diabetes Association. Standards of medical care in diabetesd2008. Diabetes Care 2008;31(Suppl. 1):S12-S54
18. Rodbard HW, Blonde L, Braithwaite SS, et al.; AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the managementofdiabetes mellitus. Endocr Pract 2007;13(Suppl. 1):1-68
19. Ryan EA, Shandro T, Green K, et al. Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes 2004;53:955-962
20. Clarke WL, Cox DJ, Gonder-Frederick LA, Julian D, Schlundt D, Polonsky W. Reduced awareness of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic frequency and associated symptoms. Diabetes Care 1995;18:517-522
21. The NIH CIT Consortium Chemistry Manufacturing Controls Monitoring Committee. Purified human pancreatic islets (PHPI) master production batch recordda standard operating procedure of the NIH Clinical Islet Transplantation Consortium [article online], 2014. Available from http://www.cellr4.org/wp-content/uploads/2014/04/CellR4-CIT-Master-Batch-Record-SOP-Title-page.pdf. Accessed 20 October 2015
22. O'Connell PJ, Holmes-Walker DJ, Goodman D, et al.; Australian Islet Transplant Consortium. Multicenter Australian trial of islet transplantation: improving accessibility and outcomes. Am J Transplant 2013;13:1850-1858
23. Brooks AM, Walker N, Aldibbiat A, et al. Attainment of metabolic goals in the integrated UK islet transplant program with locally isolated and transported preparations. Am J Transplant 2013;13:3236-3243
24. Naziruddin B, Wease S, Stablein D, et al. HLA class I sensitization in islet transplant recipients: report from the Collaborative Islet Transplant Registry. Cell Transplant 2012;21: 901-908
25. Kaneku H. 2012 annual literature review of donor-specific HLA antibodies after organ transplantation. Clin Transpl 2012;207-217
26. Gruessner RW, Gruessner AC. The current state of pancreas transplantation. Nat Rev En-docrinol 2013;9:555-562
27. Diem P, Redmon JB, Abid M, et al. Gluca-gon, catecholamine and pancreatic polypeptide secretion in type I diabetic recipients of pancreas allografts. J Clin Invest 1990;86:2008-2013
28. Kendall DM, Rooney DP, Smets YF, Salazar Bolding L, Robertson RP. Pancreas transplantation restores epinephrine response and symptom recognition during hypoglycemia in patients with long-standing type I diabetes and autonomic neuropathy. Diabetes 1997;46:249-257
29. McCoy RG, Van Houten HK, Ziegenfuss JY, Shah ND, Wermers RA, Smith SA. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care 2012;35:1897-1901
30. Ly TT, Nicholas JA, Retterath A, Lim EM, Davis EA, Jones TW. Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial. JAMA 2013;310: 1240-1247
31. Bergenstal RM, Klonoff DC, Garg SK, et al.; ASPIRE In-Home Study Group. Threshold-based insulin-pump interruption for reduction of hy-poglycemia. N Engl J Med 2013;369:224-232
32. Yeh HC, Brown TT, Maruthur N, et al. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis. Ann Intern Med 2012;157:336-347
33. Dagogo-Jack S, Rattarasarn C, Cryer PE. Reversal of hypoglycemia unawareness, but not defective glucose counterregulation, in IDDM. Diabetes 1994;43:1426-1434
34. Cranston I, Lomas J, Maran A, Macdonald I, Amiel SA. Restoration of hypoglycaemia awareness in patients with long-duration insulin-dependent diabetes. Lancet 1994;344:283-287
35. Fanelli CG, Epifano L, Rambotti AM, et al. Me-ticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglyce-mia in intensively treated patients with short-term IDDM. Diabetes 1993;42:1683-1689
36. Little SA, Leelarathna L, Walkinshaw E, et al. Recovery of hypoglycemia awareness in longstanding type 1 diabetes: a multicenter 2 3 2 factorial randomized controlled trial comparing insulin pump with multiple daily injections and continuous with conventional glucose self-monitoring (HypoCOMPaSS). Diabetes Care 2014;37:2114-2122
37. de Zoysa N, Rogers H, Stadler M, et al. A psy-choeducational program to restore hypoglycemia awareness: the DAFNE-HART pilot study. Diabetes Care 2014;37:863-866
38. Beck RW, Raghinaru D, Wadwa RP, Chase HP, Maahs DM, Buckingham BA; In Home Closed Loop Study Group. Frequency of morning keto-sis after overnight insulin suspension using an automated nocturnal predictive low glucose suspend system. Diabetes Care 2014;37:1224-1229
39. Haidar A, Legault L, Messier V, Mitre TM, Leroux C, Rabasa-Lhoret R. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial. Lancet Diabetes Endocri-nol 2015;3:17-26
40. Bartlett ST, Markmann JF, Johnson P, et al. Reportfrom IPITA-TTS opinion leaders meeting on the future of beta-cell replacement. Transplantation 2016;100(Suppl. 2):S1-S44